Travere officer files $2.9M stock sale notice

An officer of Travere Therapeutics filed a Rule 144 notice to sell 44,674 shares of TVTX common stock acquired through prior equity awards.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) has an officer, Jula Inrig, filing a notice of proposed sale of common stock under Rule 144. The notice lists common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around September 15, 2026, with a quantity of 44,674 shares and an aggregate market value of $2,939,102.46, while the company reports 94,261,082 common shares outstanding.

The securities to be sold were acquired from the issuer through equity compensation, including stock options exercised for 32,395 shares on September 15, 2026, restricted stock units vesting for 7,662 shares on January 1, 2023, and performance stock units vesting for 4,617 shares on February 10, 2025. The notice states that the securities to be sold were acquired upon vesting of restricted stock units during the period from January 1, 2023 through January 31, 2025.

Key Figures

Common shares listed in proposed transaction: 44,674 shares Aggregate market value of listed shares: $2,939,102.46 Common shares outstanding: 94,261,082 shares +3 more

6 metrics

Common shares listed in proposed transaction 44,674 shares Securities information section of the Rule 144 notice

Aggregate market value of listed shares $2,939,102.46 Value associated with the 44,674 common shares in the notice

Common shares outstanding 94,261,082 shares Reported outstanding common shares of Travere Therapeutics, Inc.

Shares from exercise of stock options 32,395 shares Acquired from issuer on September 15, 2026

Shares from restricted stock units 7,662 shares Acquired from issuer on January 1, 2023

Shares from performance stock units 4,617 shares Acquired from issuer on February 10, 2025

Key Terms

Rule 144, Restricted Stock Units, Performance Stock Units, Exercise of Stock Options

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 01/01/2023 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance Stock Units financial

"Common | 02/10/2025 | Performance Stock Units | Issuer"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Travere Therapeutics (TVTX) disclose in this Form 144 filing?

The filing reports that officer Jula Inrig submitted a Rule 144 notice for a proposed sale of common stock of Travere Therapeutics, Inc., with the sale to be executed through Morgan Stanley Smith Barney LLC on NASDAQ around September 15, 2026.

How many Travere Therapeutics (TVTX) shares are covered by this Rule 144 notice?

The notice lists 44,674 common shares of Travere Therapeutics, Inc. in connection with the proposed Rule 144 transaction, with an associated aggregate market value of $2,939,102.46 as reflected in the filing’s securities information section.

What is the aggregate market value of the TVTX shares in this Form 144?

The filing states an aggregate market value of $2,939,102.46 for the 44,674 common shares of Travere Therapeutics, Inc. listed in the securities information section of the Rule 144 notice.

How many Travere Therapeutics (TVTX) shares are outstanding according to this filing?

The Rule 144 notice reports that Travere Therapeutics, Inc. has 94,261,082 common shares outstanding, which serves as a context figure relative to the 44,674 shares referenced in the proposed sale.

How were the TVTX shares in this Form 144 acquired by the officer?

The filing explains that the securities to be sold were acquired from the issuer via equity awards: 32,395 shares from the exercise of stock options, 7,662 shares from restricted stock units, and 4,617 shares from performance stock units, with awards vesting between January 1, 2023 and February 10, 2025.

Who is the person selling Travere Therapeutics (TVTX) shares under this Rule 144 notice?

The Rule 144 notice identifies Jula Inrig as the officer for whose account the TVTX common stock is to be sold. The filing notes that she is an officer of Travere Therapeutics, Inc. and that the sale will be executed through Morgan Stanley Smith Barney LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:24 PM Accepted by SEC EDGAR 09/15/2026 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001902368
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	JULA INRIG
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	44674	2939102.46	94261082	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			32395	09/15/2026	Cash
Common	01/01/2023	Restricted Stock Units	Issuer			7662	01/01/2023	N/A
Common	02/10/2025	Performance Stock Units	Issuer			4617	02/10/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/01/2023 through 01/31/2025
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jula Inrig
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)